EXPORT CITATION

Chapter-101 Management of Obese Patient—Behavior, Diet, Activity and Treatments

BOOK TITLE: ESI Manual of Clinical Endocrinology

Author
1. Joshi Shilpa S
2. Joshi Shashank R
ISBN
9789351526476
DOI
10.5005/jp/books/12535_126
Edition
2/e
Publishing Year
2015
Pages
5
Author Affiliations
1. Mumbai Diet and Health Centre, Mumbai, Maharashtra, India
2. Grant Medical College and Sir JJ Group, Hospital, Consultant Endocrinologist, Lilavati and Bhatia Hospital, Mumbai, Maharashtra, India, Seth G.S. Medical College and K.E.M. Hospital Mumbai, Maharashtra, India, Bhatia Hospital, Joshi Clinic, Lilavati Hospital and Research Centre, A-791, Bandra Reclamation, Bandra (W), Mumbai, Maharashtra, India, Bhatia Hospital, Joshi Clinic, Lilavati Hospital and Research Centre, A-791, Bandra, Reclamation, Bandra (W), Mumbai, Maharashtra, India, S. L. Raheja Hospital, Bhatia Hospital, and Sir H. N. Hospital, Mumbai, Seth GS Medical College, Mumbai, Maharashtra, India, Lilavati and Bhatia Hospital, Mumbai, Maharashtra, India; Grant Medical College and Sir Jj Group of Hospitals, Mumbai 400 008, Maharashtra, India, Joshi Clinic, Lilavati and Bhatia Hospital; Association of Physicians of India (API), Mumbai, Maharashtra, India, Joshi Clinic, Lilavati and Bhatia Hospital; Association of Physicians of India (API), Indian Academy of Diabetes, Joshi Clinic, Mumbai, Maharashtra, Indi
Chapter keywords
Obesity, behavioral therapy, orlistat, phentermine, Liraglutide, lorcaserin

Abstract

Twenty-two million Indians are obese, especially abdominally obese. Obesity is a chronic and increasingly common disease characterized by excess body fat. The advantages, goals, and management of weight loss have been described in the chapter. Some of the strategies for weight loss and weight maintenance are diet, exercise, behavioral therapy, and functional foods. The only evidence-based and safe medication approved across the globe is orlistat (fat blockers), which inhibits the gastric lipases. This does not allow absorption of the fat in the diet. Lorcaserin, phentermine, and phentermine/topiramate combinations are approved as weight loss adjuncts in the United States but are not available in India. The novel agent for diabesity is liraglutide. The future antiobesity drugs in development are also listed out in this chapter. And finally, satiety index and medications modulating them quantifies the duration of hunger suppression by a given amount of food and the amount voluntarily eaten when the appetite returns.

Related Books

© 2019 Jaypee Brothers Medical Publishers (P) LTD.   |   All Rights Reserved

Powered by MPS ScholarStor